Goserelin 3.6 mg implant + Placebo
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postpartum Depression
Conditions
Postpartum Depression, Major Depressive Disorder, Postpartum Psychosis, Menopause, Neurodegeneration, Schizophrenia
Trial Timeline
Jan 1, 2011 โ Dec 1, 2012
NCT ID
NCT02661789About Goserelin 3.6 mg implant + Placebo
Goserelin 3.6 mg implant + Placebo is a pre-clinical stage product being developed by Brain Biotech for Postpartum Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT02661789. Target conditions include Postpartum Depression, Major Depressive Disorder, Postpartum Psychosis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02661789 | Pre-clinical | Completed |
Competing Products
20 competing products in Postpartum Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Misoprostol + Oxytocin | Cipla | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Azithromycin + Azithromycin and amoxicillin + Placebo | Merck | Approved | 85 |
| Eptacog alfa (NovoSeven) | Novo Nordisk | Approved | 84 |
| Eptacog alfa (activated) | Novo Nordisk | Pre-clinical | 22 |
| aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| fibrinogen concentrate + Placebo | CSL | Phase 1/2 | 40 |
| SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules | Biogen | Phase 3 | 74 |
| SAGE-217 + Placebo | Biogen | Phase 3 | 74 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| LPCN 1154A + Placebo | Lipocine | Phase 3 | 69 |
| ZULRESSO (brexanolone) injection | Supernus Pharmaceuticals | Pre-clinical | 18 |
| Placebo + SAGE-547 90 ฮผg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| ZULRESSOยฎ | Supernus Pharmaceuticals | Approved | 80 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 2 | 47 |
| Placebo + SAGE-547 60 ฮผg/kg/h + SAGE-547 90 ฮผg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| GH001 | GH Research | Phase 2 | 47 |
| Brexanolone | Brain Biotech | Pre-clinical | 15 |